463 results about "Ischemic vascular dementia" patented technology

The invention discloses novel carbamate compounds (I-1 to I-4) and pharmaceutically acceptable salts thereof, a preparation method of the compounds, and application of the compounds in preparation of medicines for preventing neurodegenerative diseases, including but not limited to vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV (human immunodeficiency virus) related cretinism, multiple sclerosis, progressive lateral spinal sclerosis, neuropathic pain, glaucoma and the like.

The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils.

A method for delivering a biologic to a human with Alzheimer's-related dementia, comprising administering the biologic parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human's head below the horizontal. The method further includes delivering a TNF antagonist to the brain of a human for treating mild cognitive impairment, Alzheimer's related dementia, or vascular dementia, comprising administering the TNF antagonist golimumab parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human in a Trendelenburg position, for delivery of the golimumab to the brain via the human's vertebral venous system.

Computer modeling of interactions between and among cortico and subcortical areas of the human brain, for example in a normal and a pathological state resembling schizophrenia which pathological state has inputs representing the effects of a drug(s), for the purpose of using the outputs to predict the effect of drugs in psychiatric and cognitive diseases. A method is provided for developing a computer model of interactions between and among cortico and subcortical areas of the human brain which comprises the steps of identifying data relating to a biological state of a generic synapse model, the striatum, Locus Coeruleus, Dorsal raphe, hippocampus, amygdala and cortex; identifying biological processes related to the data, these identified biological processes defining at least one portion of the biological state of the generic synapse model, the striatum, Locus Coeruleus, Dorsal raphe, hippocampus, amygdala, and cortex; and combining the biological processes to form a simulation of the biological state of interactions between and among cortico and subcortical areas of the human brain. Diseases that can be modeled include psychiatric disorders, such as schizophrenia, bipolar disorder, major depression, ADHD, autism, obsessive-compulsive disorder, substance abuse and cognitive deficits therein and neurological disorders such as Alzheimer's disease, Mild Cognitive impairment, Parkinson's disease, stroke, vascular dementia, Huntington's disease, epilepsy and Down syndrome. A resulting computer model is of the biological state of interactions between and among cortico and subcortical areas of the human brain, comprising code to define the biological processes related to the biological state of the generic synapse model, the striatum, Locus Coeruleus, Dorsal raphe, hippocampus, amygdala and cortex, and code to define the mathematical relationships related to interactions among biological variables associated with the biological processes. At least two of the biological processes are associated with the mathematical relationships. A combination of the code to define the biological processes and the code to define the mathematical relationships define a simulation of the biological state of the interactions between and among cortico and subcortical areas of the human brain. Computer executable software code is provided comprised of code to define biological processes related to a biological state of interactions between and among cortico and subcortical areas of the human brain including code to define mathematical relations associated with the biological processes. A computer model of interactions between and among cortico and subcortical areas of the human brain is provided, comprising a computer-readable memory storing codes and a processor coupled to the computer-readable memory, the processor configured to execute the codes. The memory comprises code to define biological processes related to the biological state of interactions between and among cortico and subcortical areas of the human brain, and code to define mathematical relationships related to interactions among biological variables associated with the biological processes.

The present invention relates generally to a method for computer-aided quantitative diagnosis of cerebrovascular and neurodegenerative diseases (such as Alzheimer's, vascular dementia, mild cognitive impairment, transient ischemia, stroke etc.) via a vasomotor reactivity index (VMRI) which is computed on the basis of a computational model of the dynamic nonlinear inter-relationships between beat-to-beat time-series measurements of cerebral blood flow velocity, arterial blood pressure and end-tidal CO2. This model is obtained by means of a method pioneered by the inventors and may incorporate additional physiological measurements from human subjects. Its purpose is to provide useful information to physicians involved in the diagnosis and treatment of cerebrovascular and neurodegenerative diseases with a significant neurovascular component by offering quantitative means of assessment of the effects of the disease or medication on cerebral vasomotor reactivity. Initial results from clinical data have corroborated the diagnostic potential of this approach.

The invention relates to a composite of active ingredients of Chinese herb medicine used for preventing the damage of cerebral ischemia and relevant diseases, in particular to a preparation which is prepared by the active ingredients of the Chinese herb medicine; the preparation is prepared by the active ingredients of the Chinese herb medicine and the conventional preparation technique which is used by carriers permitted by pharmacy, and comprises the following components with the parts by weight: 2 to 10 parts of ginsenoside Rb, 2 to 10 parts of ginsenoside Rg1, 1 to 5 parts of ginsenoside Rd, 1 to 5 parts of ginsenoside Re, 2 to 10 parts of stilbene glycoside, 1 to 5 parts of ginkgolide and 1 to 5 parts of flavonoid mixture which consists of kaempferol and quercetin with the weight rate to be 1:1. The invention has the advantages that the defects that in the traditional compounded Chinese medicine, the composition is complex, the product quality is not controlled effectively and the curative effect is not stable are overcome, has clear ingredients, definite effect, stable quality and obvious control effect on ischemic stroke, sequela, cerebral arteriosclerosis and vascular dementia, can improve the functions of motor nerve, and learning and memory of the patients, has low toxicity and simple preparation method without obvious side effect and is suitable for industrial mass production.

Embodiments of the invention can provide systems and methods for analyzing and assessing dementia and dementia-type disorders by integrating the use of electroencephalography (EEG), neuropsychological or cognitive testing data, and cardiovascular risk factor data. Embodiments of the invention can provide systems and methods for early detection of dementia, including Alzheimer's disease (AD), vascular dementia (VAD), mixed dementia (AD and VAD), MCI, and other dementia-type disorders. Embodiments of the invention can provide some or all of the following improvements over conventional systems and methods, including: (1) Increased sensitivity, specificity, and overall accuracy; (2) Detection of AD, VAD and mixed dementia; and (3) Accurate detection of mild dementia and some cases of mild cognitive impairment in addition to the detection of moderate to severe dementia.

A method is provided that includes identifying that a subject is at risk of suffering from vascular dementia (VaD). Responsively to the identifying, a risk of development of the VaD is reduced by applying electrical stimulation to a site of the subject selected from the group consisting of: a sphenopalatine ganglion (SPG), a greater palatine nerve, a lesser palatine nerve, a sphenopalatine nerve, a communicating branch between a maxillary nerve and an SPG, an otic ganglion, an afferent fiber going into the otic ganglion, an efferent fiber going out of the otic ganglion, an infraorbital nerve, a vidian nerve, a greater superficial petrosal nerve, and a lesser deep petrosal nerve; and configuring the stimulation to induce at least one neuroprotective occurrence selected from the group consisting of: an increase in cerebral blood flow of the subject, and a release of one or more neuroprotective substances. Other embodiments are also described.

The invention discloses a novel 2-hydroxyl chalcone compound (I), as well as pharmacy acceptable salt, preparation method, medical composition, and purpose thereof in preparing medicines for treating and/or preventing neurodegenerative diseases including but not limited to vascular dementia, Alzheimer's diseases, Parkinson's diseases, Huntington's diseases, dementia relevant to HIV, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma and the like (As shown in the description.).

The invention discloses a type of novel flavone alkylamine compounds with the formula (I) and pharmaceutically acceptable salts, a preparation method, a pharmaceutical composition and application in preparation of medicines for treating and/or preventiung neurodegeneration related diseases. The diseases comprise but are not limited to vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV related dementia, multiple sclerosis, progressive lateral sclerosis, neuropathic pain, glaucoma and other neurodegeneration diseases.

The invention discloses a 4-carbamate-3-methoxy cinnamic acid cyclamine alkyl amide compound, and a preparation method and application thereof. The compound prepared in the invention has low toxic and side effect, and can treat neurodegenerative diseases including, but not limited to, vascular dementia, the Alzheimer's disease, the Parkinson's disease, the Huntington's disease, HIV-associated dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma and the like.

The invention relates to a novel scutellarin aglycon 4 (1)-position carbamate derivant (1), a preparation method and the application thereof. A pharmacological experiment proves that the compounds have obvious inhibitory activity of acetylcholinesterase and have protective effect with different degrees on PC12 cell trauma induced by H2O2, so the compounds can be used for preparing the drugs for treating neurodegenerative diseases such as vascular dementia, AD (presenile dementia), etc.

The invention discloses 2-hydroxychalcone amine compounds and pharmaceutically-acceptable salts, preparation method thereof, pharmaceutical composition, and uses for preparing medicines treating and/or preventing neurodegenerative related diseases, the diseases including but not limited to vascular dementia, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, HIV associated dementia, multiple sclerosis, progressive lateral sclerosis, neuropathic pain, glaucoma and other neurodegenerative diseases.

The invention relates to application of sodium alginate oligose and a derivative to treatment of vascular dementia. The sodium alginate oligose and the derivative of the sodium alginate oligose are particularly mannuronic acid oligose or mannuronic acid oligose with a carboxyl at a 1-position of a reducing end and the derivative or a pharmaceutically acceptable salt, formed by connecting a beta-D-mannuronic acid through a 1,4-glucosidic bond.

The invention discloses a novel carbamate chalcone compound represented by a formula I shown in the description and pharmaceutically acceptable salts thereof, a preparation method for the novel carbamate chalcone compound and the pharmaceutically acceptable salts thereof, a pharmaceutical composition and use of the pharmaceutical composition in the preparation of drugs for treating and/or preventing neurodegenerative related diseases, including, but not limited to neurodegenerative diseases such as vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV related cretinism, multiple sclerosis, progressive lateral spinal sclerosis, neuropathic pain and glaucoma.

The invention relates to application of a Gastrodiaelata Blume plant extract containing parishin derivants on preparing a medicament for preventing and treating vascular dementia and other diseases. The invention also relates to a method for preparing the plant extract extracted and refined from Gastrodiaelata Blume plant, wherein active components are the parishin derivants, in particular to parishin A, B and C. The method adopts alcohol extraction; and an extract is refined and purified by a chromatogram method to obtain the plant extract with the content of the parishin derivants of 35 percent, in particular over 50 percent. A medicament preparation optimally selects injections, troches, capsules, soft capsules, oral liquid or dropping pills and the like.

Relating to the medicine field, the invention discloses the use of acetagastrodine in preparing medicines to prevent and treat vascular dementia and Alzheimer disease. The invention also provides a medicinal composition for preventing and treating senile dementia and its capsule as well as sustained release agent. Animal tests show that: acetagastrodine can substantially enhance the learning and memory abilities of rats with vascular dementia, reduce the activity of AchE in brains, enhance the vitality of ChAT in brains, and remarkably reduce Glu content; acetagastrodine has significant protective effect on damaged PC12 cells caused by H2O2 by enhancing the vitality of SOD and total ATP enzyme in PC12 cells and reducing the content of MDA and LD; acetagastrodine can substantially enhance the learning and memorizing abilities of AD model rats, enhance the CAT content in brains of the model rats, reduce the MAO vitality and simultaneously prevent the decrease of neurotransmitters. Acetagastrodine is better than gastrodin in terms of the treatment effects on VD and AD, and enjoys good clinical application prospect.

An orally taken Chinese medicine for treating vascular dementia is prepared from fleece flower root, astragalus root, Chinese angelica root, Chuan-xiong rhizome and lucid ligustrum fruit.

The invention provides an injection composition containing oxiracetam and a preparation method and an application thereof. The composition contains sodium hydroxide. The invention further provides a preparation method and an application of the medicinal composition. The composition is mainly used for improving memory and the memory learning function of a mentally retarded patient, and is suitablefor memory and amentia caused by symptoms such as mild or moderate vascular dementia, senile dementia, brain trauma and the like, or is taken as an auxiliary treatment medicament.

The invention provides a phenethyl alcohol glycoside-containing callicarpa kochiana extractive. The main component of the attractive is phenethyl alcohol glycosides compound. The preparation method of the extractive comprises the steps of: extracting the stem leaf of callicarpa kochiana to obtain extracting solution by reflowing water or 50-75% (v/v) alcohol; and purifying the extracting solution with macroporous resin to the extractive, wherein the extractive comprises 40-55% (w/w) forsythoside A and 10-30% (w/w) verbascoside. The animal experiment shows that the extractive can strengthen or improve the learning and memory functions to normal mice and various model animals with damaged memory, and can be used for preparing the medicine for curing the senile dementia and particularly preparing the medicine for curing vascular dementia (VD).